Bioventix plc ("Bioventix" or the "Company") Director dealingsBioventix plc (AIM: BVXP) was notified on 22 October 2014 that on the same day,due to institutional investor demand, the following directors dealt in theordinary shares of 5 pence each ("Ordinary Shares") in the Company:Name Position Type of Number Price Ordinary Percentage transaction of per shares and of Ordinary Ordinary Ordinary voting Shares and Shares Share rights held voting (pence) following rights held the following transaction the transactionIan Non-Executive Disposal 8,000* 655.0 32,000 0.6Nicholson ChairmanPeter Chief Executive Disposal 80,000** 655.0 761,176 15.1Harrison* 4,000 of which were held in the name of his wife** 25,000 of which were held in the name of his wifeFor further information please contact:Bioventix plc Tel: 01252 728 001Peter Harrison Chief Executive OfficerfinnCap Ltd Tel: 020 7220 0500Geoff Nash/Simon Hicks Corporate FinanceSteve Norcross Corporate BrokingAbout Bioventix plc:Bioventix (www.bioventix.com) specialises in the development and commercialsupply of high-affinity monoclonal antibodies with a primary focus on theirapplication in clinical diagnostics, such as in automated immunoassays used inblood testing. The antibodies created at Bioventix are generated in sheep andare of particular benefit where the target is present at low concentration andwhere conventional monoclonal or polyclonal antibodies have failed to produce asuitable reagent. Bioventix currently offers a portfolio of antibodies tocustomers for both commercial use and R&D purposes, for the diagnosis ormonitoring of a broad range of conditions, including heart disease, cancer,fertility, thyroid function and drug abuse. Bioventix currently suppliesantibody products and services to the majority of multinational clinicaldiagnostics companies. Bioventix is based in Farnham, UK and its shares aretraded on AIM under the symbol BVXP.